{"id":59740,"date":"2025-07-12T14:09:09","date_gmt":"2025-07-12T14:09:09","guid":{"rendered":"https:\/\/www.europesays.com\/us\/59740\/"},"modified":"2025-07-12T14:09:09","modified_gmt":"2025-07-12T14:09:09","slug":"this-molecular-shield-might-stop-pollen-before-it-wrecks-your-nose","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/59740\/","title":{"rendered":"This \u2018Molecular Shield\u2019 Might Stop Pollen Before It Wrecks Your Nose"},"content":{"rendered":"

Every year, pollen seasons grow longer and more intense<\/a>\u2014to the great misery of those suffering from pollen allergies\u2014myself included. There\u2019s only so much one can do with antihistamines or hot towels, and no amount of protective measures\u2014masks, firmly shut windows, you name it\u2014appears to offer any protection from the endless sneezing, runny noses, and itchy eyes.\u00a0<\/p>\n

But what if, by spraying something akin to a nasal spray, you could thwart the onslaught of those pesky allergens before they latch onto your sensitive nasal passages? <\/p>\n

This was the \u201csimple but powerful idea\u201d that inspired Kaissar Tabynov<\/a>, who led the efforts to create a \u201cmolecular shield\u201d that intercepts allergens the moment they approach our airways. For the experiment, they targeted mugwort pollen, which is the most common cause of pollen allergy<\/a> in Central Asia and Europe. Tabynov and colleagues reported the first proof-of-principle for this technology, in this instance with mice, in a paper published today in Frontiers in Immunology<\/a>.<\/p>\n

\u201cAllergies are often viewed as inconvenient but minor conditions, yet for millions, they severely reduce quality of life and can even be life-threatening,\u201d Tabynov, director of the International Center for Vaccinology at Kazakh National Agrarian Research University in Kazakhstan, told Gizmodo in an email. \u201cWe believe this could be the beginning of a new class of anti-allergy interventions\u2014smart, fast, and easy to use\u2014that could protect people during allergy season in a way no existing therapy does.\u201d\u00a0<\/p>\n

Here\u2019s how the \u201cshield\u201d works. Researchers first develop a monoclonal antibody, or a lab-made protein designed to attach to a specific molecule. In this case it\u2019s aimed at a major allergy-causing protein found in mugwort pollen. These antibodies are applied to the nose, effectively snatching the allergens away from our natural antibodies, which trigger allergic responses when bound with allergens.\u00a0<\/p>\n

The immune system is an intricate network of cells and hormones, so adjusting the treatment such that it wouldn\u2019t disrupt the natural system of mice proved to be a major challenge, explained Tabynov. Not only that, mugwort pollen is actually a combination of multiple allergy-causing particles (partly the reason they\u2019re so insufferable), meaning Tabynov\u2019s team had to focus on the most clinically relevant parts of the allergen complex.\u00a0<\/p>\n

After several adjustments, the team succeeded in making an antibody treatment that curbed nasal inflammation and asthma symptoms in mice, and it did so without harming the animals\u2019 natural antibodies. Although the duration of the treatment was shorter than Tabynov hoped, he told Gizmodo that he and his team have already devised a strategy to potentially make the treatment last longer.<\/p>\n

\u201cWhat\u2019s exciting about our approach is that it shows how precise, targeted biologics can be used not just for chronic therapy but for prevention, delivered right where allergens strike,\u201d Tabynov added. \u201cOur approach is non-invasive, needle-free, and fast-acting [and] reduces the allergen load on the immune system and may help prevent the progression of allergic rhinitis into more severe conditions such as bronchial asthma.\u201d<\/p>\n

As fellow pollen allergy sufferers are aware, allergic reactions tend to set off a chain reaction of misery throughout the body. The idea of blocking allergens before they ever reach the nose would be a huge relief for many patients, especially those with medical complications that prevent them from taking standard antihistamine pills. It\u2019d also be a time-saving, cheaper alternative to immunotherapy sessions, which can take years to have any effect.\u00a0<\/p>\n

So, is this something we\u2019ll be picking up at a local pharmacy any time soon? Depends. Tabynov\u2019s most optimistic estimate is that the first human-based studies could happen within two to three years. Additional adjustments will be needed to extend the treatment\u2019s protective effects on human nasal surfaces. But for lifelong pollen patients, it sounds like a promising start.<\/p>\n","protected":false},"excerpt":{"rendered":"Every year, pollen seasons grow longer and more intense\u2014to the great misery of those suffering from pollen allergies\u2014myself…\n","protected":false},"author":3,"featured_media":59741,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[14208,34153,210,67,132,68],"class_list":{"0":"post-59740","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-allergy","9":"tag-bioengineering","10":"tag-health","11":"tag-united-states","12":"tag-unitedstates","13":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114840663784513304","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/59740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=59740"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/59740\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/59741"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=59740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=59740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=59740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}